Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 16Active not recruiting 7Suspended 3Not yet recruiting 3Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Allogeneic Stem Cell Transplantation 1

Interventions

pembrolizumab 5Radiotherapy 4Radiation 4ALT-803 4fludarabine 3Prednisone 3Etoposide 3Cytarabine 3Cyclophosphamide 3Cisplatin 3sacituzumab govitecan 2daratumumab 2atezolizumab 2Vincristine 2Temozolomide 2Surveys and Questionnaires 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Irinotecan 2Gemcitabine 2Doxorubicin 2Blood Specimen Collection 2Biopsy 2Bevacizumab 2Androgen Antagonists 2130-nm albumin-bound paclitaxel 2zimberelimab 1vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × decitabine and cedazuridine drug combination × 90 days × Clear all
NCT06297629 2026-05-15

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡